$26.52
5.86% yesterday
Nasdaq, Jun 27, 10:11 pm CET
ISIN
US92686J1060
Symbol
VKTX
Sector
Industry

Viking Therapeutics, Inc. Stock price

$26.52
-0.66 2.43% 1M
-14.64 35.57% 6M
-13.72 34.10% YTD
-24.25 47.76% 1Y
+23.72 847.14% 3Y
+19.26 265.29% 5Y
+19.46 275.64% 10Y
+17.56 195.98% 20Y
Nasdaq, Closing price Fri, Jun 27 2025
-1.65 5.86%
ISIN
US92686J1060
Symbol
VKTX
Sector
Industry

Key metrics

Basic
Market capitalization
$3.0b
Enterprise Value
$2.1b
Net debt
$-851.9m
Cash
$851.9m
Shares outstanding
112.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 1,985.63
EV/Sales
- | 1,417.73
EV/FCF
negative
P/B
3.52
Financial Health
Equity Ratio
96.91%
Return on Equity
-12.49%
ROCE
-20.33%
ROIC
-
Debt/Equity
0.00
Financials (TTM | estimate)
Revenue
$0.0 | $1.5m
EBITDA
$-171.9m | $-219.8m
EBIT
$-172.3m
Net Income
$-128.2m | $-216.4m
Free Cash Flow
$-134.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -46.00%
EBIT
-50.67%
Net Income
-36.83% | -96.77%
Free Cash Flow
-144.20%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -14,656.22%
EBIT
-
Net
- | -14,424.72%
Free Cash Flow
-
More
EPS
$-1.15
FCF per Share
$-1.19
Short interest
30.42%
Employees
46.00
Rev per Employee
$0.00
Show more

Is Viking Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Viking Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Viking Therapeutics, Inc. forecast:

22x Buy
88%
3x Hold
12%

Analyst Opinions

25 Analysts have issued a Viking Therapeutics, Inc. forecast:

Buy
88%
Hold
12%

Financial data from Viking Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 53 53
43% 43%
-
- Research and Development Expense 119 119
55% 55%
-
-172 -172
-
-
- Depreciation and Amortization 0.46 0.46
-
-
EBIT (Operating Income) EBIT -172 -172
51% 51%
-
Net Profit -128 -128
37% 37%
-

In millions USD.

Don't miss a Thing! We will send you all news about Viking Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Viking Therapeutics, Inc. Stock News

Positive
The Motley Fool
2 days ago
Shares in biopharmaceutical company Viking Therapeutics (VKTX 4.76%) were up by 6.3% at 12:30 a.m. ET today. The move likely stems from the market digesting the previous day's news that Viking had initiated a phase 3 trial of its most promising program in its pipeline, namely VK2375, a treatment for metabolic disorders, including obesity.
Positive
The Motley Fool
2 days ago
Growth stocks are having a moment. Several small- and mid-cap stocks have suddenly jumped 40% or more in the past 30 days.
Negative
Investors Business Daily
3 days ago
Viking Therapeutics stock remains under pressure, but analysts said Wednesday the company's strategy for its Phase 3 studies could pay off.
More Viking Therapeutics, Inc. News

Company Profile

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Head office United States
CEO Brian Lian
Employees 46
Founded 2012
Website vikingtherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today